Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy

Circulation Research

Volumn 94, Issue 1, 2004, Pages 110-118

  Wilkins, Benjamin J ^a   Dai, Yan Shan ^a   Bueno, Orlando F ^a   Parsons, Stephanie A ^a   Xu, Jian ^a   Plank, David M ^a   Jones, Fred ^a   Kimball, Thomas R ^a   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Calcineurin; Heart failure; Hypertrophy; Signaling; Transcription

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; GROWTH HORMONE; LUCIFERASE; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN C; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCINEURIN ABETA GENE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; EXERCISE; GENE; GENE EXPRESSION; GENE TARGETING; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; REPORTER GENE; TRANSGENIC MOUSE;

ANIMALS; CALCINEURIN; CARDIOMEGALY; CELL SIZE; CELLS, CULTURED; DNA-BINDING PROTEINS; FEMALE; GENES, REPORTER; HEART FAILURE, CONGESTIVE; INSULIN-LIKE GROWTH FACTOR I; LUCIFERASES; MALE; MICE; MICE, TRANSGENIC; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; PHYSICAL CONDITIONING, ANIMAL; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0347320747     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000109415.17511.18     Document Type: Article

References (42)

1. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
2. Ho KK, Levy D, Kannel WB, Pinsky JL. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22:6-13.
3. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072.
4. Oakley D. General cardiology: the athlete's heart. Heart. 2001;86:722-726.
5. Molkentin JD, Dorn GW 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426.
6. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79.
7. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109(suppl):S67-S79.
8. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
9. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol. 2002;541:1-8.
10. Ritter O, Hack S, Schuh K, Rothlein N, Perrot A, Osterziel KJ, Schulte HD, Neyes L. Calcineurin in human heart hypertrophy. Circulation. 2002;105:2265-2269.
11. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999;5:246-247.
12. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103:670-677.
13. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bio Essays. 2002;24:65-71.
14. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-2548.
15. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799-2809.
16. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA. 2002;99:12333-12338.
17. Shiojima I, Yefremashvili M, Luo Z, Kureishi Y, Takahashi A, Tao J, Rosenzweig A, Kahn CR, Abel ED, Walsh K. Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem. 2002;277:37670-37677.
18. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R, Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002;277:22896-22901.
19. Musaró A, McCullagh KJA, Naya FJ, Olson EN, Rosenthal N. IGF-I induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature. 1999;400:581-585.
20. 2+-dependent calcineurin signaling pathway. Nature. 1999;400:576-580.
21. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2000;97:1196-1201.
22. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101:2863-2869.
23. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98:3328-3333.
24. NHLBI Program for Genomic Applications Beth Israel Deaconess Medical Center, 2003. Available at: http://www.cardiogenomics.org. Accessed November 14, 2003.
25. Tanaka N, Ryoke T, Hongo M, Mao L, Rockman HA, Clark RG, Ross J Jr. Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. Am J Physiol. 1998;275:H393-H399.
26. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart: cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem. 2000;275:13571-13579.
27. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C, Maggi A. Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol. 2001;15:1104-1113.
28. Lim HW, De Windt LJ, Steinberg L, Taigen T, Witt SA, Kimball TR, Molkentin JD. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation. 2000;101:2431-2437.
29. Luo Z, Shyu KG, Gualberto A, Walsh K. Calcineurin inhibitors and cardiac hypertrophy. Nat Med. 1998;4:1092-1093.
30. Tsao L, Neville C, Musaro A, McCullagh KJ, Rosenthal N. Revisiting calcineurin and human heart failure. Nat Med. 2000;6:2-3.
31. Neri Serneri GG, Boddi M, Modesti PA, Cecioni I, Coppo M, Padeletti L, Michelucci A, Colella A, Galanti G. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res. 2001;89:977-982.
32. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD. Impaired cardiac hypertrophic response in calcineurin Aβ-deficient mice. Proc Natl Acad Sci USA. 2002;99:4586-4591.
33. Naya FJ, Wu C, Richardson JA, Overbeek P, Olson EN. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development. 1999;126:2045-2052.
34. Schmidt-Ullrich R, Memet S, Lilienbaum A, Feuillard J, Rapheal M, Israel A. NF-κB activity in transgenic mice: developmental regulation and tissue specificity. Development. 1996;122:2117-2128.
35. DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development. 1999;126:4557-4568.
36. Balke CW, Shorofsky SR. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res. 1998;37:290-299.
37. Shibasaki F, Price ER, Milan D, McKeon F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature. 1996;382:370-373.
38. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000;87:731-738.
39. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S. Phosphoinositide 3-kinase (p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003;100:12355-12360.
40. Eto Y, Yonekura K, Sonoda M, Arai N, Sata M, Sugiura S, Takenaka K, Gualberto A, Hixon ML, Wagner MW, Aoyagi T. Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation. 2000;101:2134-2137.
41. Wu H, Rothermel B, Kanatous S, Rosenberg P, Naya FJ, Shelton JM, Hutcheson KA, DiMaio JM, Olson EN, Bassel-Duby R, Williams RS. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J. 2001;20:6414-6423.
42. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW II, Kitsis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res. 2000;86:255-263.